Drug Trial Radar · NCT06912763
Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Aug 8, 2025
Primary completion
Jul 31, 2030
Study completion Jul 31, 2031
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Supportive care
- FDA-regulated drug
- Yes
- Who can join
- Female only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To find out if adding medication can help treat or prevent lymphedema and/or fibrosis related to radiation therapy, in survivors of head and neck cancer. Researchers will compare these drugs to find the most effective therapy for preventing or limiting these side effects.
Conditions
- Fibrosis Syndrome
- Lymphedema
- Head &Amp; Neck Cancer
- Fibrosis
Interventions
Pravastatin (drug)Drug
Given PO
PentoxifyllineDrug
Given PO
ketoprofenDrug
Given PO
PirfenidoneoneDrug
Given PO
Standard of Care (SOC)Other
SOC
tocopherolDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and adverse eventsTime frame: Through study completion; an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MD Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.